Full Press Release Details
Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results
On track to enroll first patient in Phase 1/2 clinical trial of GPH101 for sickle cell disease in the second half of 2021
Expanded leadership team with hiring of CSO and three new appointments to board of directors
Completed upsized initial public offering of common stock, raising $273.7 million in gross proceeds
SOUTH SAN FRANCISCO, Calif., Aug 12, 2021 - (BUSINESSWIRE) - Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing high-efficiency precision gene correction to treat or cure serious diseases, today reported recent business progress and second quarter 2021 financial results.
"This has been a transformational period for Graphite Bio as we advance our next-generation gene editing platform to precisely find and replace any gene in the genome. We have built an outstanding team of experienced industry leaders and, with our recent initial public offering, are well-resourced to advance our pipeline into clinical development, led by GPH101, a highly differentiated gene correction approach for sickle cell disease," said Josh Lehrer, M.Phil., M.D., chief executive officer of Graphite Bio. "We are focused on executing on our mission to develop potential one-time cures for patients who have a wide range of serious and life-threatening diseases, starting with sickle cell. We remain on track to enroll the first patient in our Phase 1/2 clinical trial of GPH101 in the second half of 2021, with initial proof-of-concept data expected by the end of 2022."
Second Quarter Financial Highlights
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency precision gene correction to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing platform that could enable a variety of applications to transform human health and achieve one of medicine's most elusive goals: to precisely "find & replace" any gene in the genome. Graphite Bio's platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our gene editing platform and our product candidates, and the timing for enrollment of the first patient in our Phase 1/2 clinical trial of GPH101 and the availability of initial proof-of-concept data, may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions.
Any forward-looking statements in this press release are based on Graphite Bio's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that we may encounter delays in patient enrollment and in the initiation, conduct and completion of our planned clinical trials. These risks concerning Graphite Bio's programs and operations are described in additional detail in its final prospectus for the initial public offering, which was filed with the SEC on June 28, 2021. Graphite Bio explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Condensed Statements of Operations
(In thousands, except share and per share data)
| Three Months Ended | Six months ended | ||||||||||||||||||
| June 30, | June 30, | ||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||
| Operating expenses*: | |||||||||||||||||||
| Research and development | $ | 12,667 | $ | 423 | $ | 18,044 | $ | 423 | |||||||||||
| General and administrative | 4,866 | 869 | 8,857 | 990 | |||||||||||||||
| Total operating expenses | 17,533 | 1,292 | 26,901 | 1,413 | |||||||||||||||
| Loss from operations | (17,533 | ) | (1,292 | ) | (26,901 | ) | (1,413 | ) | |||||||||||
| Other income (expense), net: | |||||||||||||||||||
| Other income (expense), net: | 4 | - | 4 | - | |||||||||||||||
| Related party convertible note interest expense | - | (20 | ) | - | (40 | ) | |||||||||||||
| Change in fair value of the Series A redeemable convertible preferred stock tranche liability | - | - | (10,341 | ) | - | ||||||||||||||
| Total other income (expense), net | 4 | (20 | ) | (10,337 | ) | (40 | ) | ||||||||||||
| Net loss and comprehensive loss | $ | (17,529 | ) | $ | (1,312 | ) | $ | (37,238 | ) | $ | (1,453 | ) | |||||||
| Net loss per share attributable to common stockholders - basic and diluted | $ | (3.45 | ) | $ | (0.56 | ) | $ | (8.45 | ) | $ | (1.25 | ) | |||||||
| Weighted-average shares used in computing net loss per share attributable to common stockholders - basic and diluted | 5,087,008 | 2,329,402 | 4,405,357 | 1,164,700 | |||||||||||||||
| * Includes stock-based compensation as follows | |||||||||||||||||||
| Research and development | $ | 614 | $ | - | $ | 811 | $ | - | |||||||||||
| General and administrative | 1,404 | 1 | 2,240 | 1 | |||||||||||||||
| Total stock-based compensation expense | $ | 2,018 | $ | 1 | $ | 3,051 | $ | 1 |
Condensed Balance Sheets
| June 30, | December 31, | |||||||||
| 2021 | 2020 | |||||||||
| Assets | ||||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 381,965 | $ | 19,782 | ||||||
| Restricted cash | 149 | 35 | ||||||||
| Prepaid expenses and other current assets | 2,638 | 1,286 | ||||||||
| Total current assets | 384,752 | 21,103 | ||||||||
| Property plant and equipment, net | 2,343 | 1,461 | ||||||||
| Other assets | 11 | - | ||||||||
| Total assets | $ | 387,106 | $ | 22,564 | ||||||
| Liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit) | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable | $ | 4,046 | $ | 630 | ||||||
| Accrued compensation | 723 | 466 | ||||||||
| Accrued expenses and other current liabilities | 3,089 | 1,890 | ||||||||
| Series A redeemable convertible preferred stock tranche liability | - | 29,062 | ||||||||
| Total current liabilities | 7,858 | 32,048 | ||||||||
| Other liabilities | 64 | 316 | ||||||||
| Total liabilities | 7,922 | 32,364 | ||||||||
| Series A redeemable convertible preferred stock | - | 55,608 | ||||||||
| Stockholders' equity (deficit): | ||||||||||
| Common stock | 1 | - | ||||||||
| Additional paid-in capital | 487,012 | 5,183 | ||||||||
| Accumulated deficit | (107,829 | ) | (70,591 | ) | ||||||
| Total stockholders' equity (deficit) | 379,184 | (65,408 | ) | |||||||
| Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit) | $ | 387,106 | $ | 22,564 |
VP, Communications and Investor Relations